FOSUN INTL LTD UNSP/ADR - FOSUY STOCK NEWS

Fosun International has achieved a significant milestone in S&P Global's 2024 Corporate Sustainability Assessment (CSA), scoring 70 points and ranking in the top 5% among global peers. This represents an improvement from their previous score of 68 points and top 6% ranking last year, significantly outperforming the industry average of 30 points.

The company received balanced scores across key dimensions: 72 in governance and economic, 68 in environmental, and 71 in social aspects. Notable achievements were recorded in Business Ethics, Environmental Policy, Energy, Climate Strategy, Risk Management, Human Capital Development, and Customer Relationship Management.

Fosun's commitment to ESG is further evidenced by its inclusion in S&P Global's Sustainability Yearbook 2024, its AA rating from MSCI ESG (unique among Greater China conglomerates), and its consistent presence in the FTSE4Good Index Series. The company recently launched its sustainable development strategy 'Create IMPACT' to drive innovation and global sustainability initiatives.

Fosun International has been awarded the prestigious 'Outstanding ESG Award' along with 'Best in ESG Practices' and 'Best in ESG Report' at the TVB ESG Awards ceremony held on December 13, 2024, in Hong Kong. The company, which operates in over 35 countries across healthcare, tourism, consumption, and insurance sectors, was recognized for its comprehensive ESG management system and sustainable development initiatives.

Notable achievements include their commitment to peak carbon emissions by 2028 and achieve carbon neutrality by 2050, the establishment of a Carbon Neutrality Committee, and significant healthcare innovations. Their pharmaceutical division has made breakthrough developments, including Yi Kai Da, the first CAR-T cell therapy approved in mainland China, and artesunate injections that have treated over 72 million severe malaria patients globally.

The company has implemented its 'Create IMPACT' sustainable development strategy, focusing on innovation, mindful operation, people-oriented approach, advanced governance, climate positivity, and transparency.

Atlantis Sanya hosts the 2024 China Mermaid Open Grand Final and Asian Cup on December 12th-13th, marking the first Asian Cup for mermaid sports. Over 70 top athletes from various Asian countries and regions compete at the Ambassador Lagoon, featuring 13,500 tonnes of seawater and an 11-metre-deep open-air setting.

The event, jointly hosted by multiple Chinese sports authorities and Fosun Tourism Group, represents a significant step toward internationalizing mermaid sports. The venue's 16.5-metre-wide, 10-metre-high acrylic viewing panel allows spectators to witness the underwater performances up close.

This marks the fourth consecutive year Atlantis Sanya has hosted the Mermaid Open, contributing to Hainan's development as a sports tourism destination and supporting China's national sports development strategies.

Fosun International (HKEX: 00656) has received five prestigious ESG awards from two global media outlets, highlighting its excellence in environmental, social, and governance practices. The company earned the ESG Leading Enterprise Award and ESG Leading Social Initiatives Award from Bloomberg Businessweek/Chinese Edition, alongside three awards from Global Banking and Finance Review.

The company's achievements include its 'Create IMPACT' sustainable development strategy, focusing on Innovation, Mindful Operation, People and Partner Orientation, Advanced Governance, Climate and Planet Positivity, and Transparency. Notable initiatives include the Rural Doctors Program, which has supported 25,000 rural doctors and benefited 3 million grassroots families, and their malaria treatment program, which has treated over 68 million patients globally.

Fosun International maintains an MSCI ESG Rating of AA, outperformed 94% of global peers in S&P Global's Corporate Sustainability Assessment, and operates responsibly in more than 35 countries and regions.

Fosun's Rural Doctors Program has been selected as one of the '20 Cases of Private Sector's Sustainable Development in China for 20 Years' by the United Nations Global Compact (UNGC). The program, launched in 2017, has reached 78 counties across 16 provinces in China, supporting 25,000 rural doctors and benefiting 3 million grassroots families. Fosun, which holds an MSCI ESG rating of 'AA', is the only conglomerate in Greater China to achieve this rating. The program has received multiple recognitions, including the 'National Advanced Collective in Poverty Alleviation' and 'China Charity Award'.

Fosun, China's largest private investor in Portugal, marks a decade of significant market presence since 2014. The company has built a robust ecosystem focused on insurance, banking, and healthcare through key investments: Fidelidade (Portugal's largest insurer), Luz Saúde (major healthcare group), and Millennium BCP (largest listed private bank). Fidelidade reported €2.808 billion in premiums (+5.9% YoY) and €104 million net income (+5.3% YoY) as of June 2024. The company has expanded to 13 countries, with international operations contributing over 30% of total premiums and 40% of profits. Digital transformation initiatives have shown success, with Fidelidade's app reaching 1.6 million users and BCP achieving €856 million in net profit in 2023.

Fosun International (HKEX: 00656) has been awarded The Asset ESG Corporate Awards 2024 - Platinum Award and Best Initiative in Social Responsibility at a ceremony in Singapore. The company's ESG strategy 'Create IMPACT' demonstrates its commitment to sustainable development.

Fosun has achieved significant milestones in ESG performance, being the only Greater China conglomerate rated AA by MSCI ESG Ratings and ranking in the top 1% of S&P Global's Sustainability Yearbook 2024 (China Edition). The company's innovations include breakthrough medical treatments, with Fosun Pharma's artesunate injection treating over 68 million malaria patients globally.

The company's 'WE Volunteer' program has engaged over 4,500 employees in public welfare activities, contributing 34,476 hours. Through Fosun Foundation, established in 2012, the company supports various social initiatives, including the Rural Doctors Program which has benefited 3 million grassroots families.

Fosun participated in the 7th China International Import Expo (CIIE), showcasing its latest healthcare innovations at the Fosun Pharma booth. The company highlighted several breakthrough products, including the Ion Robotic Bronchoscopy system, which received domestic approval in March 2024 and completed its first commercial application in September. The company also presented the new V2 model of the Exablate Neuro FUS system for treating neurological disorders. Fosun's participation has helped transform many exhibits into market-ready products, with the company investing RMB 3.5 billion in technological innovation in the first half of the year.

Fosun International (FOSUY) and Standard Chartered China signed a memorandum of understanding for strategic cooperation during the Seventh China International Import Expo. The agreement aims to expand their global market cooperation, particularly in 'Belt and Road' markets. Standard Chartered will provide comprehensive financial services, including cash management, trade financing, and sustainable financial solutions to support Fosun's global operations. This marks their third strategic cooperation memorandum since their initial partnership in 2007. Fosun International maintains operations in over 35 countries, serving both family and corporate customers through its global business presence.